ARCHIVES

FDA News: FDA Taking Comments on “First Generic” ANDA Process

This article is from The Cancer Letter archive.

Vol. 40 No. 44 | November 21, 2014

Download PDF Visit The Full Archive

Related Articles

GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL

July 26, 2013

In Brief: Construction Grant Application Deadline for 75-25% Funding Oct. 1; Fordham Quits

April 29, 1977

H. Lee Moffitt Center Reads The Cancer Letter

July 19, 2002

Final Issue of ‘76

December 10, 1976

ONS Scientific Program Grows

June 20, 1980

Congress Urges CMS To Soften Proposal For Coverage Of ESAs in Oncology.

July 20, 2007